Fistulas, strictures, obstruction, anemia, cancer risk, extraintestinal symptoms, and related complications.
Page 1 of 20 · 916 articles
Subtopics
MSC therapy and its interaction with autophagy could point to new ways to boost cell-based treatments for IBD. For people with Crohn's disease or ulcerative colitis, this could eventually lead to different therapeutic...
The paper describes a plant-derived polysaccharide that reduced inflammation, improved barrier proteins, and shifted gut microbiota in a mouse model of ulcerative colitis—mechanisms relevant to IBD. If replicated and...
The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...
The paper points to a specific RNA-modifying protein (YTHDF2) that appears to drive inflammatory signaling and pyroptotic cell death in lab models of ulcerative colitis; targeting this pathway could open new avenues for...
The study identifies a prebiotic-encapsulated extracellular vesicle approach that reduced colitis severity and early kidney stress in a mouse model, pointing to the gut microbiota and barrier function as key mediators....
The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.
People hospitalized with acute severe ulcerative colitis face a high risk of steroid failure and need for rescue therapy or colectomy. This trial explores whether adding the JAK inhibitor tofacitinib to corticosteroids...
The study describes a new small-molecule approach that reduced inflammation in mouse models of ulcerative colitis by targeting NF-κB transcription (p65 G-quadruplex). That suggests a potential future drug pathway...
This study describes a new preclinical approach to reduce inflammation in IBD by degrading NLRP3 rather than merely inhibiting it. For people following IBD therapeutic research, degraders could offer longer-lasting...
Postoperative intra-abdominal abscesses are a common, serious short-term complication after ileocecal surgery in children with Crohn’s disease and can lengthen hospital stay and delay restarting medical treatment.
Hospitalized patients with moderate-to-severe ulcerative colitis flares sometimes need escalation to biologic or surgical treatments. This trial is testing whether a short course of HBOT can improve symptoms and reduce...
Upadacitinib is an approved oral JAK1 inhibitor with evidence for inducing and maintaining remission in moderate-to-severe Crohn's disease, including colonic-predominant disease. Patients and clinicians may consider it...
If epithelial cells keep lasting "memories" of past inflammation or microbial signals, that could help explain why some people with IBD have persistent barrier dysfunction, relapses, or incomplete mucosal recovery even...
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from Inflammatory bowel diseases.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Complications. The original article is from BMJ case reports.
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
If you or someone with MS is treated with rituximab (an anti‑CD20 drug), this study suggests a small increased risk of developing IBD—mostly Crohn’s disease—over time. That risk is rare but may affect treatment decisions...
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this...
Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...
IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Middle East journal of digestive...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Long-term risk of needing another intestinal surgery is a major concern for people with Crohn’s disease. This study suggests laparoscopic resection may be linked to lower long-term reoperation risk compared with open...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
People with Crohn’s disease facing pelvic exenteration or urinary diversion may worry that using ileal tissue is unsafe. This study suggests ileal conduits can be done but carry higher urological complication and...
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
If endometriosis is linked to other immune, allergic, or chronic pain conditions, people with endometriosis may benefit from broader evaluation and coordinated care beyond gynecology. The review suggests shared...
Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This work suggests a new experimental target (extracellular vimentin) that reduced inflammation, fibrosis-related markers, and necroptotic cell-death markers in mice and in cultured colon cells — processes that are...
This trial is testing a novel stem-cell infusion approach aimed at treating Crohn’s disease and ulcerative colitis, so people with IBD may be interested in emerging cell-therapy options and safety data. Phase 1 studies...
This study looks directly at whether failing multiple biologic drugs before elective subtotal colectomy affects short-term surgical outcomes for people with ulcerative colitis — information that can help patients and...
MMF-associated enterocolitis can look like other serious causes of colitis and may be underrecognized in lung transplant patients. Correctly identifying MAE can avoid misdiagnosis and inappropriate treatments.
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
Families and clinicians often wonder whether H. pylori infection in childhood affects risks for asthma, IBD, celiac disease, or other immune-mediated disorders.
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This study highlights a potential microbiome–bile acid–immune pathway that could be relevant to ulcerative colitis and suggests a traditional herbal formula may influence that pathway in mice. Patients interested in...
People with ulcerative colitis may be interested because the study suggests a combined probiotic approach could strengthen gut bacteria functions linked to a protective metabolite (spermidine) and reduce colitis-like...
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing...
